Viktor Drvota

Chief Executive Officer & Chief Investment Officer at Karolinska Development AB

Viktor Drvota

Viktor Drvota

Chief Executive Officer & Chief Investment Officer at Karolinska Development AB

Overview
Career Highlights

Karolinska Development AB
Karolinska Development AB (Private Equity)

RelSci Relationships

305

Number of Boards

24

Birthday

01/01/1965

Age

53

Relationships
RelSci Relationships are individuals Viktor Drvota likely has professional access to. A relationship does not necessarily indicate a personal connection.

Senior Advisor at Industrifonden

Relationship likelihood: Strong

Former Acting Chief Executive Officer at Karolinska Development AB

Relationship likelihood: Strong

Former Vice President, Clinical Development at Karolinska Development AB

Relationship likelihood: Strong

Procurator at KTH Chalmers Capital KB

Relationship likelihood: Strong

Co-Founder at Dilafor AB

Relationship likelihood: Strong

Investment Manager at Industrifonden

Relationship likelihood: Strong

Senior Scientist at Johnson & Johnson

Relationship likelihood: Strong

Partner at HealthCap AB

Relationship likelihood: Strong

Chief Executive Officer & Director at Rolfsen Consulting AB

Relationship likelihood: Strong

Senior Advisor at Lipidor AB

Relationship likelihood: Strong

Paths to Viktor Drvota
Potential Connections via
Relationship Science
You
Viktor Drvota
Chief Executive Officer & Chief Investment Officer at Karolinska Development AB
Education
Ph.D. Unknown

Karolinska Institutet is a medical university in Solna within the Stockholm urban area, Sweden, and one of Europe's largest and most prestigious medical universities. It was founded in 1810 on Kungsholmen on the west side of Stockholm; the main campus was relocated decades later to Solna, just outside Stockholm. A second campus was established more recently in Flemingsberg, Huddinge, south of Stockholm.

Career History
Chief Executive Officer & Chief Investment Officer
2015 - Current

Karolinska Development AB engages in the investment in pharmaceutical business. It focuses on identifying medical innovations and investing in the creation and growth of companies that develop these assets into differentiated products that will make a difference to patient's lives. The company was founded in 2006 and is headquartered in Solna, Sweden.

Chief Executive Officer
2016 - 2017

KD's investment approach aims to transfer life sciences innovations into commercial applications while improving human health. They are an early investor with the objective of being the lead investor. They generally maintain a significant position in their portfolio firms until exit. They endeavor to rapidly build value in high risk opportunities.Among key investment criteria, they seek innovations, either pharmaceutical or medical technology applications, which address unmet medical needs. KD looks for opportunities displaying a strong IP position, preferably with a patent application, as well as unique skills or processes.KD works closely with regional Nordic academic and research institutions. Their deal flow agreement with Karolinska Institutet Innovations ensures priority access of promising opportunities at a very early stage. In addition to capital infusion, the firm supports their investments through business development expertise, technical specialists and access to their wide-ranging professional network.

Head-Investment Area Life Science
2002 - 2016

SEB VC is an active, long-term manager which makes venture capital investments in growth companies in the technology, life science and industrial sectors, aiming to add competence and provide a network for investee companies. The firm focuses on companies which have a unique product or service with a sustainable competitive edge, a highly skilled management team who are also partners in the company and a business concept with international market potential.SEB VC takes a minority position in their investee companies, seeking board representation and making investments up to SEK 80 million.

Boards & Committees
Director
2016 - Current

OssDsign AB designs and manufactures implants and material technology for bone replacement. It is an orthopedic medical device company that develops implantable products. It develops pioneering implants for bone healing with focus on cranial surgery. The firm's product OssDsign Cranio PSI is an implant for skull reconstruction. It uses new design solutions, material compositions, and manufacturing processes mainly based on proprietary bioceramic technologies. The company was by Håkan Gunnar Engqvist, Carl Thomas Engstrand, Bo Erik Qwarnstrom, and Jonas Åberg in May 2011 and is headquartered in Uppsala, Sweden.

Chairman
Current

Part of InDex Pharmaceuticals Holding AB, InDex Diagnostics AB is a company headquartered in Solna, Sweden. The firm manufactures pharmaceutical products. Peter Hakim Zerhouni is the current CEO, occupying that position since 2015.

Director
Current

Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Viktor Drvota. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Viktor Drvota's profile does not indicate a business or promotional relationship of any kind between RelSci and Viktor Drvota.